All News
Filter News
Found 78 articles
-
Ozette Technologies Announces New Collaboration with Umoja Biopharma to Accelerate Biomarker Discovery in Preclinical Studies
6/21/2023
Ozette Technologies, Inc. today announced its collaboration with Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers.
-
Umoja Biopharma to Present at the 2023 BIO International Convention
5/31/2023
Umoja Biopharma, Inc. announced that the Company will present on its mission, pipeline, technological platforms, and partnering approach at the 2023 BIO International Convention taking place June 5-8, 2023 in Boston, MA.
-
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
5/17/2023
Umoja Biopharma, Inc. today announced the presentation of new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting demonstrating potent in vivo CAR T cell generation and robust anti-tumor activity using its VivoVec™ platform.
-
Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting
5/3/2023
Umoja Biopharma, Inc. announced today that it will have one oral presentation and one poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, to be held May 16-20, 2023, in Los Angeles.
-
IASO Bio Raises Nearly $75 Million in Series C1 Funding
1/17/2023
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today announced the completion of nearly US $75 million ($500 million RMB) in Series C1 funding.
-
BioSpace’s exclusive Hotbed Maps highlights nine different regions to watch across the U.S. The maps, made in vibrant color for BioSpace showcases a one-of-a-kind glance at some of 2023’s headline-making companies.
-
Umoja Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Umoja Biopharma, Inc. announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 in San Francisco, CA.
-
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors
12/14/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced the appointment of Dieter Weinand to its Board of Directors where he will take on the role of Chair, effective November 17, 2022.
-
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
11/21/2022
Umoja Biopharma, Inc. and IASO Biotherapeutics announced today that they have entered into a research agreement to evaluate Umoja's iCIL platform with IASO's best-in-class CARs,
-
Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/10/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced today new data from three poster presentations at the 2022 Society for Immunotherapy of Cancer 37th Annual Meeting.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Expansion Therapeutics Appoints Raymond Kelleher, M.D., Ph.D., to its Board of Directors
10/26/2022
Expansion Therapeutics, Inc. today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.
-
Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10/19/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have three poster presentations at the 2022 Society for Immunotherapy for Cancer 37th Annual Meeting.
-
Umoja Biopharma Appoints Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board
9/13/2022
Umoja Biopharma, Inc. announced the appointment of Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board.
-
Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development
9/6/2022
Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round.
-
Umoja CEO Andy Scharenberg spoke with BioSpace about the company's unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.
-
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech's most exciting hotbeds.
-
Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer
8/8/2022
Pyramid Biosciences, Inc. today announced the expansion of its senior leadership team. Nushmia Khokhar, MD has joined the company as Chief Medical Officer.
-
Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation
7/28/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced new data at the 2022 iPSC Manufacturing Summit held in Boston, Mass.
-
Enavate Sciences Appoints Industry Veteran Robert Glassman as Executive Vice President, Search & Evaluation
7/11/2022
Enavate Sciences , a platform launched by Patient Square Capital to support transformative therapeutic companies, announced today the appointment of Robert Glassman, M.D., as Executive Vice President, Search & Evaluation.